Why India's patent battles matter
01 May 2008
Four pharmaceutical patent cases being argued in India will have a big impact on healthcare issues in the region. Peter Ollier looks at what is at stake
When Indian drug maker Cipla decided that it wanted to make its own version of erlotinib, the lung cancer medication marketed by Roche as Tarceva, it didn't do it quietly. Instead of filing a post-grant opposition or requesting a licence, the company announced the launch to the media and boasted of the lower price it could offer. Presumably, it also put its legal team on a state of high alert. In essence, the company said "We're copying – come and get us". Many people at the time asked whether such an aggressive strategy would backfire in court....
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial